Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Debt / NOTE 0.250% 3/0
-
Unit price / market price
-
$0.9957
-
Total 13F principal
-
$728,633,184
-
Principal change
-
+$25,041,143
-
Total reported value
-
$726,115,830
-
Number of holders
-
64
-
Value change
-
+$9,607,370
-
Number of buys
-
29
-
Number of sells
-
22
Institutional Holders of HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 as of Q2 2025
As of 30 Jun 2025 HALOZYME THERAPEUTICS INC - NOTE 0.250% 3/0 had 64 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of $728,633,184 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Linden Advisors LP, Opti Capital Management, LP, Point72 Asset Management, L.P., STEELHEAD PARTNERS LLC, LAZARD ASSET MANAGEMENT LLC, BlackRock, Inc., Calamos Advisors LLC, Wellesley Asset Management, CITADEL ADVISORS LLC, and MILLENNIUM MANAGEMENT LLC.
This table shows 64 bond principal holders of the security as of 30 Jun 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.